More Stories

Informist, Friday, Dec. 26, 2025

 

MUMBAI – Pharmaceutical stocks are likely to remain rangebound next week with analysts focusing on partnerships, capacity expansions, and key domestic policy developments. Analysts are bullish on generic drugmakers, who are expected to benefit from the upcoming Indian patent expiry of Novo Nordisk's anti-diabetic and weight loss treatment drug, the glucagon-like-peptide-1 or GLP-1 molecule semaglutide.

 

"The Nifty Pharma index has been consolidating for around 15 months and further consolidation is likely, said Anshul Jain, technical analyst at Laxmishree Investments and Securities. The analyst, however, said he was "very bullish" on Glenmark Pharmaceuticals and Mankind Pharma due to their performance on technical charts. Any significant upside is seen only after Nifty Pharma breaches the 23200 mark, according to Jain. On Friday, the Nifty Pharma index closed at 22684.65 points, down nearly 1% over the last three sessions.

 

Analysts expect the GLP-1 drug to rapidly increase its market share after the semaglutide drug goes off-patent. GLP-1 drugs are estimated to eventually account for 4–5% of the Indian pharmaceutical market and up to 25–30% of the diabetes segment, Elara Securities said in a report. This shift could lift the overall growth in the Indian pharma market by 1–2 percentage points over the next three to five years, the brokerage said. However, the brokerage expects the insulin market to shrink by 10-15% as GLP-1 gains popularity. Generic players in India are preparing to scale their GLP-1 production as Semaglutide goes off-patent.

 

Several deals are in focus as analysts continue to monitor how companies prepare for the GLP-1 sales competition. Ajanta Pharma signed an in-licensing agreement with Biocon for semaglutide, which is a GLP-1 receptor agonist. The brokerage Prabhudas Lilladher expects the company to achieve a higher market share and has raised its 2027-28 (Apr-Mar) sales estimate by 3.5% to INR 69.66 billion.

 

Analysts will be monitoring domestic policy developments. Last week, the Director General of Trade Remedies notified a "minimum import price" on certain key active pharmaceutical ingredients and intermediates due to concerns about disruptive pricing by Chinese companies.

 

TOP HEADLINES

 

* Novo Nordisk gets US FDA OK for semaglutide pill for weight loss
* Zydus Life arm partners with Bioeq for commercialisation of Nufymco in US
* Ajanta Pharma signs in-licensing pact with Biocon for marketing Semaglutide
* Laurus Labs buys 49 mln shrs of KRKA Pharma for INR 490 mln via rights issue
* US FDA classifies Emcure Pharma's Gujarat unit as 'no action indicated'
* GLP-1 drugs may account for 4-5% of India's total pharma mkt - Elara Capital
* Aurobindo Pharma arm Helix to buy 20% more in Chinese JV Luoxin Aurovitas
* Granules India board OKs raising INR 17.63 bln via warrants, equity shares
* HC allows Zydus Life to manufacture semaglutide, export to some nations
* Glenmark Pharma's US arm launches Epinephrine injection vials
* Biocon Biologics gets full rights for Adalimumab from Fujifilm Kyowa Kirin
* Ruby QC Investment sells 4.6% stake in Akums Drugs via block deal on Monday
* Emcure Pharma launches semaglutide injection Poviztra starting INR 8,790/mo
* Granules India arm gets US FDA tentative approval for amphetamine tablets
* Nine pharma cos sign price cut pact with US, pledge $150 bln invest in mfg
* US FDA issues 5 observations to Granules India's Hyderabad arm
* IPO Alert: Symbiotec Pharmalab files DRHP for issue of up to INR 21.8 bln

 

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	28905.00	3.10	29338.30	28208.30
Alkem Laboratories	5535.00	(-)0.40	5614.30	5468.30
Aurobindo Pharma	1208.30	(-)1.40	1228.10	1193.90
Biocon	395.45	(-)0.80	404.10	389.80
Cipla	1506.00	(-)0.70	1520.50	1486.70
Divi's Laboratories	6427.50	(-)0.80	6603.80	6313.80
Dr Reddy's Laboratories	1269.30	(-)0.70	1282.40	1254.60
Gland Pharma	1653.50	(-)1.10	1686.50	1617.50
GlaxoSmithKline Pharmaceuticals	2464.30	(-)2.60	2500.20	2441.60
Glenmark Pharmaceuticals	2010.60	0.90	2035.20	1992.00
Granules India	617.35	5.80	627.90	604.20
Ipca Laboratories	1439.80	1.10	1475.90	1380.10
Laurus Labs	1085.00	3.80	1094.50	1074.10
Lupin	2112.40	(-)0.60	2129.70	2087.10
Natco Pharma	908.50	(-)0.90	926.60	897.20
Pfizer	5052.30	(-)0.90	5110.10	4972.10
Sanofi India	4095.30	0.70	4147.80	4055.80
Sun Pharmaceutical Industries	1719.50	(-)1.50	1750.50	1692.50
Torrent Pharmaceuticals	3816.60	0.40	3865.30	3778.10
Zydus Lifesciences	911.55	(-)0.90	924.50	902.50
Nifty Pharma	22684.65	(-)0.30	22884.40	22531.80
Nifty 50	26042.30	0.30	26200.60	25929.40
S&P Bse Sensex	85041.45	0.10	85560.00	84678.60

 

 

End

 

Reported by Eshitva Prakash

Edited by Saji George Titus

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000/+91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.